Table 3

Oncologic outcomes by study group

OutcomeNo. (%) of patients;* residencep value
Urban and suburban
n = 219
Rural and remote
n = 55
Tumour size, cm, median (IQR)4.0 (2.5–6.5)5.0 (2.7–8.2)0.07
Location of tumour0.74
 Antrum47 (21)8 (15)
 Body32 (15)8 (15)
 Cardia8 (4)2 (4)
 Pylorus1 (0.5)0 (0)
Lauren classification0.14
 Intestinal44 (20)7 (13)
 Diffuse26 (12)9 (16)
 Mixed9 (4)0 (0)
Pathologic stage0.31
 02 (1)0 (0)
 I51 (23)11 (20)
 II25 (11)9 (16)
 III61 (28)13 (24)
 IV34 (16)14 (25)
Grade0.97
 I14 (6)3 (5)
 II59 (27)14 (25)
 III128 (58)32 (58)
pT stage0.014
 T04 (2)0 (0)
 T134 (16)9 (16)
 T227 (12)3 (5)
 T342 (19)22 (40)
 T466 (30)12 (22)
pN stage0.36
 N057 (26)15 (27)
 N126 (12)5 (9)
 N234 (16)6 (11)
 N355 (25)21 (38)
Total no. of lymph nodes resected, median (IQR)28 (21–39)28 (21–43)0.64
No. of positive lymph nodes, median (IQR)2 (0–9)5 (0–16)0.23
LV invasion79 (36)21 (38)0.27
PN invasion65 (30)22 (40)0.34
pM stage0.67
 M0142 (65)37 (67)
 M131 (14)10 (18)
Site of metastasis0.12
 Peritoneum23 (11)7 (13)
 Liver2 (1)0 (0)
 Nonregional lymph nodes6 (3)1 (2)
 Bone0 (0)1 (2)
Invasion into surrounding structure0 (0)1 (2)
pCR4 (3)0 (0)0.58
Follow-up time, mo, median (IQR)18 (6–37)11 (6–39)0.40
  • IQR = interquartile range; LV = lymphovascular; M = distant metastasis; N = lymph node metastasis; p = pathologic or post-treatment; pCR = pathologic complete response; PN = perineural; T = tumour extension.

  • * Unless indicated otherwise.

  • Greatest dimension of tumour as measured by pathologist.